Skip to content

Biohaven BHVN Current ratio

Current ratio at other companies

Eli Lilly logo
Eli LillyLLY
1.5×+0.1×
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
27.8×+10.1×
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
27.1×-3.9×
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
7.1×+0.3×
uniQure logo
uniQureQURE
10.4×-1.6×
Roivant Sciences logo
Roivant SciencesROIV
18.4×-15.1×

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.23B-48.1%
Enterprise value$2.23B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×

Where this comes from

Calculated from Biohaven’s reported figures.

Based on the most recent quarter.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's current ratio?
Biohaven (BHVN) reported current ratio of 7.4× in Q1 2026.
How has Biohaven's current ratio changed year-over-year?
Biohaven's current ratio increased by 217.4% year-over-year, from 2.3× to 7.4×.
What is the long-term trend for Biohaven's current ratio?
Over 4 years (2021 to 2025), Biohaven's current ratio has grown at a 8.9% compound annual growth rate (CAGR), from 2.3× to 3.2×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.